Chronic spontaneous urticaria, Allergic asthma, Chronic rhinosinusitis with nasal polyps research hub

A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.

This study is comparing a new version of a common medicine, Xolair, with the original. It's looking at how the new medicine works in the body, its safety, and if it causes an immune reaction. This is for healthy people, not those with existing conditions.